Showing results (201-210 of 396) with videos related to

Sort By:
Pageof 40
Ocular Immunology and Inflammation|July 7, 2022
Experts Opinion: OCTA vs. FFA/ICG in Uveitis - Which Will Survive?Alessandro Invernizzi, Ester Carreño, Francesco Pichi, et al.
Retina (Philadelphia, Pa.)|April 8, 2025
Retinal Sarcoidosis: A Case Series with New Insights from Multi-Modal Imaging of 23 LesionsPrakshi Chopra, Federico Zicarelli, Marco Pellegrini, et al.
The British Journal of Ophthalmology|May 27, 2017
Progression of lamellar hole-associated epiretinal proliferation and retinal changes during long-term follow-upDenise Compera, Ricarda G Schumann, Matteo G Cereda, et al.
The British Journal of Ophthalmology|December 4, 2018
Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 monthsAlessandro Invernizzi, Kelvin Teo, Vuong Nguyen, et al.
BMC Ophthalmology|January 11, 2020
Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE studyGiovanni Staurenghi, Justus G Garweg, Bianca S Gerendas, et al.
Ophthalmology and Therapy|August 20, 2025
Multimodal Imaging to Assess Disease Activity and Predict Fluid Resolution in Patients with wAMD Treated with Brolucizumab: The IMAGINE StudyMarco Lupidi, Francesco Bandello, Stela Vujosevic, et al.
The British Journal of Ophthalmology|May 13, 2019
Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs studyFrancesco Bandello, Giovanni Staurenghi, Federico Ricci, et al.
The British Journal of Ophthalmology|October 4, 2017
Green emission fluorophores in eyes with atrophic age-related macular degeneration: a colour fundus autofluorescence pilot studyEnrico Borrelli, Jianqin Lei, Siva Balasubramanian, et al.
Ophthalmology|April 5, 2011
Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN studyFrank G Holz, Winfried Amoaku, Juan Donate, et al.
Ophthalmology|January 27, 2018
Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUSGiovanni Staurenghi, Timothy Y Y Lai, Paul Mitchell, et al.
Pageof 40